Drugs / MRT-6160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06597799 | Aug 2024 → Apr 2025 | — | Monte Rosa Therapeutics, Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Monte Rosa Therapeutics, Inc | Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) monterosatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT-6160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06597799 ↗ |
| Route | Oral | “Orally administered tablets or capsules of MRT-6160” NCT06597799 ↗ |